89 annotations
Page 5 of 5
we hope that in the future, it will be possible to conduct Phase III NASH trials without relying on biopsies
(No comment added)
Transcript
2023 Q4
8 Feb 24
I would say in terms of planning a Phase III for any drug in NASH, a really important priority for us is to move away as much as we can from liver biopsies and replace them with noninvasive testing.
(No comment added)
Transcript
2023 Q4
8 Feb 24
we literally just got this Phase II data so give us a chance to determine our next steps on the plans
(No comment added)
Transcript
2023 Q4
8 Feb 24
why Lilly is not initiating a Phase III trial of tirzepatide in NASH
(No comment added)
Transcript
2023 Q4
8 Feb 24
We haven't had a chance yet to talk to the FDA here at all about next steps
(No comment added)
Transcript
2023 Q4
8 Feb 24
Do you see a prospect from SYNERGY-NASH for accelerated approval?
(No comment added)
Transcript
2023 Q4
8 Feb 24
we're pretty positive on this data package as a whole and what this could mean for patients, both in terms of stopping progression of MASH and reversing fibrosis
(No comment added)
Transcript
2023 Q4
8 Feb 24
we expect to see results from the Phase III obstructive sleep apnea and Phase III heart failure studies this year.
(No comment added)
Transcript
2023 Q4
8 Feb 24
The full SYNERGY-NASH results will be presented at a medical congress later this year.
(No comment added)
Transcript
2023 Q4
8 Feb 24